{"title":"Home page","description":null,"products":[{"product_id":"retatrutide","title":"Retatrutide","description":"\u003c!-- ================================================\n     MVLabs.mx — Blog Post: Retatrutide Research Guide\n     Shopify-compatible body HTML\n     ================================================ --\u003e\n\u003cmeta charset=\"UTF-8\"\u003e\n\n\u003cstyle\u003e\n\/* ── Base ───────────────────────────────────────── *\/\n:root {\n  --mv-dark:    #0b3347;\n  --mv-primary: #0e4f68;\n  --mv-mid:     #2590b4;\n  --mv-light:   #5ab4cc;\n  --mv-pale:    #cce8f2;\n  --mv-ice:     #e8f5fa;\n  --mv-text:    #0a1e2c;\n  --mv-muted:   #456d80;\n  --mv-warn:    #b45309;\n  --mv-warn-bg: #fffbeb;\n  --radius:     14px;\n  --shadow:     0 4px 24px rgba(11,51,71,0.10);\n}\n.reta-page {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;\n  color: var(--mv-text);\n  max-width: 860px;\n  margin: 0 auto;\n  padding: 0 16px 60px;\n  line-height: 1.7;\n}\n.reta-page *, .reta-page *::before, .reta-page *::after { box-sizing: border-box; }\n\n\/* ── Hero ───────────────────────────────────────── *\/\n.reta-hero {\n  background: linear-gradient(135deg, var(--mv-dark) 0%, var(--mv-primary) 60%, var(--mv-mid) 100%);\n  border-radius: var(--radius);\n  padding: 48px 36px 40px;\n  margin-bottom: 32px;\n  color: #fff;\n  position: relative;\n  overflow: hidden;\n}\n.reta-hero::before {\n  content: '';\n  position: absolute; inset: 0;\n  background: url(\"data:image\/svg+xml,%3Csvg width='60' height='60' viewBox='0 0 60 60' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cg fill='none' fill-rule='evenodd'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Cpolygon points='30,5 55,18 55,42 30,55 5,42 5,18'\/%3E%3C\/g%3E%3C\/g%3E%3C\/svg%3E\");\n  pointer-events: none;\n}\n.reta-hero-badge {\n  display: inline-flex; align-items: center; gap: 6px;\n  background: rgba(255,255,255,0.15); border: 1px solid rgba(255,255,255,0.25);\n  border-radius: 20px; padding: 4px 14px; font-size: 12px; font-weight: 600;\n  letter-spacing: 0.06em; text-transform: uppercase; margin-bottom: 16px;\n}\n.reta-hero h1 {\n  font-size: clamp(26px, 5vw, 42px); font-weight: 900;\n  letter-spacing: -0.03em; margin: 0 0 12px; line-height: 1.1;\n}\n.reta-hero p {\n  font-size: 16px; opacity: 0.88; max-width: 560px; margin: 0 0 20px;\n}\n.reta-hero-meta {\n  display: flex; flex-wrap: wrap; gap: 16px; font-size: 13px; opacity: 0.75;\n}\n.reta-hero-meta span { display: flex; align-items: center; gap: 5px; }\n\n\/* ── Research Warning Banner ─────────────────────── *\/\n.reta-warn {\n  background: var(--mv-warn-bg); border: 1.5px solid #fcd34d;\n  border-left: 5px solid var(--mv-warn);\n  border-radius: var(--radius); padding: 16px 20px; margin-bottom: 28px;\n  font-size: 13.5px; color: #92400e; line-height: 1.6;\n}\n.reta-warn strong { color: #78350f; }\n\n\/* ── Collapsible sections ─────────────────────────── *\/\n.reta-section {\n  background: #fff; border: 1.5px solid var(--mv-pale);\n  border-radius: var(--radius); margin-bottom: 16px;\n  box-shadow: 0 2px 8px rgba(11,51,71,0.06);\n  overflow: hidden;\n}\n.reta-section \u003e details \u003e summary,\n.reta-section \u003e summary {\n  display: flex; align-items: center; justify-content: space-between;\n  padding: 20px 24px; cursor: pointer; user-select: none;\n  list-style: none; gap: 12px;\n}\n.reta-section \u003e details \u003e summary::-webkit-details-marker { display: none; }\n.reta-section \u003e details \u003e summary::marker { display: none; }\n.sec-header {\n  display: flex; align-items: center; gap: 12px;\n}\n.sec-icon {\n  width: 36px; height: 36px; border-radius: 10px; flex-shrink: 0;\n  background: var(--mv-ice); display: flex; align-items: center; justify-content: center;\n}\n.sec-icon svg { color: var(--mv-primary); }\n.sec-title { font-size: 16px; font-weight: 700; color: var(--mv-primary); }\n.sec-subtitle { font-size: 12px; color: var(--mv-muted); margin-top: 2px; }\n.sec-arrow {\n  width: 22px; height: 22px; flex-shrink: 0; color: var(--mv-mid);\n  transition: transform 0.25s;\n}\ndetails[open] .sec-arrow { transform: rotate(180deg); }\n.sec-body { padding: 0 24px 24px; }\n.sec-divider { height: 1.5px; background: var(--mv-pale); margin: 0 24px 20px; }\n\/* ── Typography inside sections ──────────────────── *\/\n.reta-page h2 { font-size: 20px; font-weight: 800; color: var(--mv-dark); margin: 0 0 14px; }\n.reta-page h3 { font-size: 15px; font-weight: 700; color: var(--mv-primary); margin: 20px 0 8px; }\n.reta-page p  { margin: 0 0 14px; font-size: 14.5px; }\n.reta-page ul, .reta-page ol { margin: 0 0 14px; padding-left: 20px; }\n.reta-page li { margin-bottom: 6px; font-size: 14.5px; }\n.reta-page a  { color: var(--mv-mid); text-decoration: underline; text-decoration-thickness: 1px; }\n.reta-page a:hover { color: var(--mv-primary); }\n\n\/* ── Key stat cards ──────────────────────────────── *\/\n.stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(140px, 1fr)); gap: 12px; margin: 16px 0 20px; }\n.stat-card {\n  background: var(--mv-ice); border: 1.5px solid var(--mv-pale);\n  border-radius: 12px; padding: 16px 14px; text-align: center;\n}\n.stat-val { font-size: 28px; font-weight: 900; color: var(--mv-primary); line-height: 1; margin-bottom: 4px; }\n.stat-lbl { font-size: 11px; color: var(--mv-muted); font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }\n.stat-sub { font-size: 10px; color: var(--mv-muted); margin-top: 3px; }\n\n\/* ── Chart container ─────────────────────────────── *\/\n.chart-wrap {\n  background: var(--mv-ice); border: 1.5px solid var(--mv-pale);\n  border-radius: 12px; padding: 20px 16px; margin: 16px 0;\n  overflow-x: auto;\n}\n.chart-title { font-size: 12px; font-weight: 700; color: var(--mv-muted); text-transform: uppercase; letter-spacing: 0.06em; margin-bottom: 14px; }\n.chart-source { font-size: 10px; color: var(--mv-muted); margin-top: 8px; text-align: right; }\n\n\/* ── Dosing table ─────────────────────────────────── *\/\n.dose-table { width: 100%; border-collapse: collapse; font-size: 13.5px; margin: 12px 0; }\n.dose-table th { background: var(--mv-primary); color: #fff; padding: 10px 12px; text-align: left; font-size: 11.5px; text-transform: uppercase; letter-spacing: 0.06em; }\n.dose-table th:first-child { border-radius: 8px 0 0 0; }\n.dose-table th:last-child  { border-radius: 0 8px 0 0; }\n.dose-table td { padding: 9px 12px; border-bottom: 1px solid var(--mv-pale); }\n.dose-table tr:last-child td { border-bottom: none; }\n.dose-table tr:nth-child(even) td { background: var(--mv-ice); }\n.dose-table .phase-col { font-weight: 600; color: var(--mv-primary); }\n.dose-table .max-row td { background: #e0f2fe !important; font-weight: 700; color: var(--mv-dark); }\n\n\/* ── Recon box ────────────────────────────────────── *\/\n.recon-box {\n  background: linear-gradient(135deg, var(--mv-dark), var(--mv-primary));\n  border-radius: 12px; padding: 20px 22px; color: #fff; margin: 16px 0;\n}\n.recon-box h3 { color: #fff; margin-top: 0; font-size: 14px; opacity: 0.85; text-transform: uppercase; letter-spacing: 0.07em; }\n.recon-formula { font-size: 20px; font-weight: 800; margin: 8px 0; letter-spacing: -0.01em; }\n.recon-detail { font-size: 13px; opacity: 0.8; }\n\n\/* ── Calculator CTA ──────────────────────────────── *\/\n.calc-cta {\n  background: linear-gradient(135deg, var(--mv-primary), var(--mv-mid));\n  border-radius: var(--radius); padding: 24px 28px;\n  display: flex; align-items: center; justify-content: space-between;\n  flex-wrap: wrap; gap: 16px; margin: 24px 0; text-decoration: none !important;\n}\n.calc-cta-text { color: #fff; }\n.calc-cta-text strong { display: block; font-size: 16px; font-weight: 800; margin-bottom: 4px; }\n.calc-cta-text span { font-size: 13px; opacity: 0.85; }\n.calc-cta-btn {\n  background: #fff; color: var(--mv-primary); font-weight: 800; font-size: 13px;\n  border-radius: 10px; padding: 10px 20px; white-space: nowrap; flex-shrink: 0;\n}\n\n\/* ── Side effects bar ─────────────────────────────── *\/\n.se-bar-wrap { margin: 6px 0 12px; }\n.se-bar-row { display: flex; align-items: center; gap: 10px; margin-bottom: 8px; font-size: 13px; }\n.se-bar-label { width: 120px; flex-shrink: 0; color: var(--mv-text); }\n.se-bar-track { flex: 1; background: var(--mv-pale); border-radius: 20px; height: 8px; overflow: hidden; }\n.se-bar-fill { height: 100%; border-radius: 20px; background: var(--mv-mid); }\n.se-bar-pct { width: 36px; flex-shrink: 0; color: var(--mv-muted); font-weight: 600; font-size: 12px; text-align: right; }\n\n\/* ── Reference chip ──────────────────────────────── *\/\n.ref-chip {\n  display: inline-flex; align-items: center; gap: 5px;\n  background: var(--mv-ice); border: 1px solid var(--mv-pale);\n  border-radius: 20px; padding: 3px 10px; font-size: 11px; color: var(--mv-muted);\n  text-decoration: none; vertical-align: middle; margin: 2px 2px;\n  transition: background 0.15s;\n}\n.ref-chip:hover { background: var(--mv-pale); color: var(--mv-primary); }\n\n\/* ── Footnotes ────────────────────────────────────── *\/\n.reta-footnotes {\n  border-top: 2px solid var(--mv-pale); margin-top: 40px; padding-top: 24px;\n}\n.reta-footnotes h4 { font-size: 12px; text-transform: uppercase; letter-spacing: 0.08em; color: var(--mv-muted); margin: 0 0 14px; }\n.fn-list { list-style: none; padding: 0; margin: 0; }\n.fn-list li { font-size: 12px; color: var(--mv-muted); margin-bottom: 8px; padding-left: 24px; position: relative; line-height: 1.5; }\n.fn-list li::before { content: attr(data-n); position: absolute; left: 0; font-weight: 700; color: var(--mv-mid); }\n.fn-list a { color: var(--mv-mid); }\nsup.fn { font-size: 10px; color: var(--mv-mid); font-weight: 700; cursor: default; }\n\n\/* ── Responsive ──────────────────────────────────── *\/\n@media (max-width: 600px) {\n  .reta-hero { padding: 32px 20px 28px; }\n  .sec-body { padding: 0 16px 20px; }\n  .reta-section \u003e details \u003e summary { padding: 16px 18px; }\n  .calc-cta { flex-direction: column; }\n  .stat-grid { grid-template-columns: repeat(2, 1fr); }\n}\n\u003c\/style\u003e\n\n\u003cdiv class=\"reta-page\"\u003e\n\n  \u003c!-- ── Hero ────────────────────────────────────────── --\u003e\n  \u003cdiv class=\"reta-hero\"\u003e\n    \u003cdiv class=\"reta-hero-badge\"\u003e\n      \u003csvg width=\"12\" height=\"12\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"M9 3H5a2 2 0 0 0-2 2v4\"\u003e\u003c\/path\u003e\u003cpath d=\"M9 3h6\"\u003e\u003c\/path\u003e\u003cpath d=\"M15 3h4a2 2 0 0 1 2 2v4\"\u003e\u003c\/path\u003e\u003cpath d=\"M3 9v6\"\u003e\u003c\/path\u003e\u003cpath d=\"M21 9v6\"\u003e\u003c\/path\u003e\u003cpath d=\"M3 15v4a2 2 0 0 0 2 2h4\"\u003e\u003c\/path\u003e\u003cpath d=\"M15 21h4a2 2 0 0 0 2-2v-4\"\u003e\u003c\/path\u003e\u003cpath d=\"M9 21h6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      Research Reference — MVLabs.mx\n    \u003c\/div\u003e\n    \u003ch1\u003eRetatrutide (LY3437943)\u003c\/h1\u003e\n    \u003cp\u003eThe first triple hormone receptor agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously — delivering bariatric-level weight loss in research settings.\u003c\/p\u003e\n    \u003cdiv class=\"reta-hero-meta\"\u003e\n      \u003cspan\u003e📋 Research use only\u003c\/span\u003e\n      \u003cspan\u003e🔬 Phase 3 data available\u003c\/span\u003e\n      \u003cspan\u003e💊 10 mg \/ vial · SKU: RT10\u003c\/span\u003e\n      \u003cspan\u003e📅 Updated June 2026\u003c\/span\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003c!-- ── Research Disclaimer ─────────────────────────── --\u003e\n  \u003cdiv class=\"reta-warn\"\u003e\n    \u003cstrong\u003e⚠ For Research Purposes Only.\u003c\/strong\u003e All protocols, dosing information, and data on this page are provided exclusively for educational and scientific research reference. Retatrutide (LY3437943) is an investigational compound. It is \u003cstrong\u003enot approved by the FDA or any regulatory authority\u003c\/strong\u003e for human use. All dosing ranges referenced are derived from published clinical research. MVLabs.mx products are strictly for in-vitro and research use only. Always consult a qualified medical professional.\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 1: What Is Retatrutide ─────────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails open\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003ccircle cx=\"12\" cy=\"12\" r=\"10\"\u003e\u003c\/circle\u003e\u003cpath d=\"M12 16v-4\"\u003e\u003c\/path\u003e\u003cpath d=\"M12 8h.01\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n            \u003cdiv class=\"sec-title\"\u003eWhat Is Retatrutide?\u003c\/div\u003e\n            \u003cdiv class=\"sec-subtitle\"\u003eOverview, molecular class \u0026amp; development status\u003c\/div\u003e\n          \u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cp\u003eRetatrutide (developmental code \u003cstrong\u003eLY3437943\u003c\/strong\u003e) is a synthetic single-peptide molecule developed by \u003cstrong\u003eEli Lilly and Company\u003c\/strong\u003e. It is the world's first \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — simultaneously activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n        \u003cp\u003eUnlike semaglutide (GLP-1 only) or tirzepatide (GLP-1\/GIP dual agonist), retatrutide adds glucagon receptor activation, which drives direct thermogenesis and hepatic fat mobilization beyond what satiety-based mechanisms alone can achieve.\u003csup class=\"fn\"\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n        \u003ch3\u003eReceptor Targets \u0026amp; Their Roles\u003c\/h3\u003e\n        \u003cdiv class=\"chart-wrap\"\u003e\n          \u003cdiv class=\"chart-title\"\u003eTriple Receptor Mechanism\u003c\/div\u003e\n          \u003csvg viewbox=\"0 0 680 220\" width=\"100%\" style=\"display:block;max-width:680px;margin:0 auto;font-family:Arial,sans-serif;\"\u003e\n            \u003cellipse cx=\"340\" cy=\"110\" rx=\"62\" ry=\"38\" fill=\"#0e4f68\" stroke=\"#2590b4\" stroke-width=\"2\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"340\" y=\"106\" text-anchor=\"middle\" font-size=\"13\" font-weight=\"800\" fill=\"#fff\"\u003eRETA\u003c\/text\u003e\n            \u003ctext x=\"340\" y=\"122\" text-anchor=\"middle\" font-size=\"10\" fill=\"#9dd4e4\"\u003eLY3437943\u003c\/text\u003e\n            \u003cellipse cx=\"100\" cy=\"60\" rx=\"80\" ry=\"34\" fill=\"#e2f5fa\" stroke=\"#2590b4\" stroke-width=\"1.5\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"100\" y=\"55\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#0e4f68\"\u003eGLP-1R\u003c\/text\u003e\n            \u003ctext x=\"100\" y=\"70\" text-anchor=\"middle\" font-size=\"10\" fill=\"#456d80\"\u003eAppetite ↓ · Insulin ↑\u003c\/text\u003e\n            \u003cellipse cx=\"340\" cy=\"32\" rx=\"80\" ry=\"28\" fill=\"#e2f5fa\" stroke=\"#2590b4\" stroke-width=\"1.5\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"340\" y=\"26\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#0e4f68\"\u003eGIPR\u003c\/text\u003e\n            \u003ctext x=\"340\" y=\"42\" text-anchor=\"middle\" font-size=\"10\" fill=\"#456d80\"\u003eInsulin ↑ · Nausea ↓\u003c\/text\u003e\n            \u003cellipse cx=\"580\" cy=\"60\" rx=\"80\" ry=\"34\" fill=\"#e2f5fa\" stroke=\"#2590b4\" stroke-width=\"1.5\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"580\" y=\"55\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#0e4f68\"\u003eGCGR\u003c\/text\u003e\n            \u003ctext x=\"580\" y=\"70\" text-anchor=\"middle\" font-size=\"10\" fill=\"#456d80\"\u003eEnergy ↑ · Fat burn ↑\u003c\/text\u003e\n            \u003cline x1=\"282\" y1=\"88\" x2=\"178\" y2=\"72\" stroke=\"#2590b4\" stroke-width=\"1.8\" stroke-dasharray=\"4,3\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"320\" y1=\"73\" x2=\"335\" y2=\"60\" stroke=\"#2590b4\" stroke-width=\"1.8\" stroke-dasharray=\"4,3\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"398\" y1=\"88\" x2=\"502\" y2=\"72\" stroke=\"#2590b4\" stroke-width=\"1.8\" stroke-dasharray=\"4,3\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n            \u003cdefs\u003e\u003cmarker id=\"ar\" markerwidth=\"6\" markerheight=\"6\" refx=\"5\" refy=\"3\" orient=\"auto\"\u003e\u003cpath d=\"M0,0 L0,6 L6,3 z\" fill=\"#2590b4\"\u003e\u003c\/path\u003e\u003c\/marker\u003e\u003c\/defs\u003e\n            \u003crect x=\"160\" y=\"162\" width=\"360\" height=\"46\" rx=\"10\" fill=\"#0e4f68\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"340\" y=\"181\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#fff\"\u003eCombined Effect\u003c\/text\u003e\n            \u003ctext x=\"340\" y=\"198\" text-anchor=\"middle\" font-size=\"11\" fill=\"#9dd4e4\"\u003eWeight loss · Improved glycemic control · Reduced visceral fat\u003c\/text\u003e\n            \u003cline x1=\"340\" y1=\"148\" x2=\"340\" y2=\"162\" stroke=\"#2590b4\" stroke-width=\"1.5\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n          \u003c\/svg\u003e\n          \u003cdiv class=\"chart-source\"\u003eAdapted from: Jastreboff et al., NEJM 2023; Nature Cell Discovery 2024 \u003csup class=\"fn\"\u003e[1,3]\u003c\/sup\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eDevelopment Timeline\u003c\/h3\u003e\n        \u003cul\u003e\n          \u003cli\u003e\n\u003cstrong\u003e2021:\u003c\/strong\u003e Phase 1 first-in-human study initiated (NCT04881760)\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eJune 2023:\u003c\/strong\u003e Phase 2 results published in \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003e2024–2026:\u003c\/strong\u003e Phase 3 TRIUMPH program (5 trials)\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003e2025:\u003c\/strong\u003e TRIUMPH-1 topline: up to \u003cstrong\u003e30.3%\u003c\/strong\u003e weight loss at 104 weeks\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eFDA Approval:\u003c\/strong\u003e Pending (NDA submission expected late 2026)\u003c\/li\u003e\n        \u003c\/ul\u003e\n        \u003cdiv style=\"display:flex;gap:8px;flex-wrap:wrap;margin-top:12px;\"\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e📄 NEJM Phase 2 Paper\u003c\/a\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04881760\" target=\"_blank\" rel=\"noopener\"\u003e🔬 ClinicalTrials.gov\u003c\/a\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\"\u003e🏢 Lilly TRIUMPH-1\u003c\/a\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n  \u003c!-- ── Section 2: Clinical Evidence ───────────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M3 3v18h18\"\u003e\u003c\/path\u003e\u003cpath d=\"m19 9-5 5-4-4-3 3\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eClinical Evidence\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003ePhase 2 \u0026amp; Phase 3 TRIUMPH trial data\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cdiv class=\"stat-grid\"\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e30.3%\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eMax weight loss\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003ePhase 3 · 104 weeks\u003c\/div\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e70.3 lb\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eAvg. lost (12 mg)\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003eTRIUMPH-1 · 80 wks\u003c\/div\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e2,339\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eParticipants\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003eTRIUMPH-1 trial\u003c\/div\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e3×\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eReceptor targets\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003eGLP-1 · GIP · Glucagon\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003ePhase 2 — Weight Loss by Dose (48 Weeks)\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\n\u003c\/h3\u003e\n        \u003cdiv class=\"chart-wrap\"\u003e\n          \u003cdiv class=\"chart-title\"\u003eMean % Body Weight Change at 48 Weeks — Phase 2 (Jastreboff et al., NEJM 2023)\u003c\/div\u003e\n          \u003csvg viewbox=\"0 0 580 200\" width=\"100%\" style=\"display:block;font-family:Arial,sans-serif;\"\u003e\n            \u003cline x1=\"60\" y1=\"20\" x2=\"60\" y2=\"155\" stroke=\"#c0d9e4\" stroke-width=\"1\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"155\" x2=\"555\" y2=\"155\" stroke=\"#c0d9e4\" stroke-width=\"1\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"118\" x2=\"555\" y2=\"118\" stroke=\"#e2f5fa\" stroke-width=\"1\" stroke-dasharray=\"4,3\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"83\" x2=\"555\" y2=\"83\" stroke=\"#e2f5fa\" stroke-width=\"1\" stroke-dasharray=\"4,3\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"48\" x2=\"555\" y2=\"48\" stroke=\"#e2f5fa\" stroke-width=\"1\" stroke-dasharray=\"4,3\"\u003e\u003c\/line\u003e\n            \u003ctext x=\"52\" y=\"159\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e0%\u003c\/text\u003e\n            \u003ctext x=\"52\" y=\"122\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e−5%\u003c\/text\u003e\n            \u003ctext x=\"52\" y=\"87\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e−15%\u003c\/text\u003e\n            \u003ctext x=\"52\" y=\"52\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e−25%\u003c\/text\u003e\n            \u003crect x=\"85\" y=\"143\" width=\"60\" height=\"12\" rx=\"3\" fill=\"#cce8f2\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"115\" y=\"138\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e−2.1%\u003c\/text\u003e\n            \u003crect x=\"195\" y=\"108\" width=\"60\" height=\"47\" rx=\"3\" fill=\"#5ab4cc\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"225\" y=\"103\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e−8.7%\u003c\/text\u003e\n            \u003crect x=\"305\" y=\"63\" width=\"60\" height=\"92\" rx=\"3\" fill=\"#2590b4\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"335\" y=\"58\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0e4f68\"\u003e−17.1%\u003c\/text\u003e\n            \u003crect x=\"415\" y=\"32\" width=\"60\" height=\"123\" rx=\"3\" fill=\"#0e4f68\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"445\" y=\"27\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0e4f68\"\u003e−22.8%\u003c\/text\u003e\n            \u003crect x=\"490\" y=\"25\" width=\"55\" height=\"130\" rx=\"3\" fill=\"#0b3347\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"517\" y=\"20\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0b3347\"\u003e−24.2%\u003c\/text\u003e\n            \u003ctext x=\"115\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003ePlacebo\u003c\/text\u003e\n            \u003ctext x=\"225\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e1 mg\u003c\/text\u003e\n            \u003ctext x=\"335\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e4 mg\u003c\/text\u003e\n            \u003ctext x=\"445\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0e4f68\"\u003e8 mg\u003c\/text\u003e\n            \u003ctext x=\"517\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0b3347\"\u003e12 mg\u003c\/text\u003e\n          \u003c\/svg\u003e\n          \u003cdiv class=\"chart-source\"\u003eSource: Jastreboff AM et al. N Engl J Med. 2023;389:514-526\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003evs. Competing Agents\u003c\/h3\u003e\n        \u003ctable class=\"dose-table\"\u003e\n          \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrug\u003c\/th\u003e\n\u003cth\u003eClass\u003c\/th\u003e\n\u003cth\u003eMax Weight Loss\u003c\/th\u003e\n\u003cth\u003eDuration\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n          \u003ctbody\u003e\n            \u003ctr\u003e\n\u003ctd\u003eSemaglutide (Wegovy)\u003c\/td\u003e\n\u003ctd\u003eGLP-1\u003c\/td\u003e\n\u003ctd\u003e−15.2%\u003c\/td\u003e\n\u003ctd\u003e68 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd\u003eTirzepatide (Zepbound)\u003c\/td\u003e\n\u003ctd\u003eGLP-1\/GIP\u003c\/td\u003e\n\u003ctd\u003e−22.5%\u003c\/td\u003e\n\u003ctd\u003e72 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr class=\"max-row\"\u003e\n\u003ctd\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eGLP-1\/GIP\/Glucagon\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e−30.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e104 weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n          \u003c\/tbody\u003e\n        \u003c\/table\u003e\n        \u003cdiv style=\"display:flex;gap:8px;flex-wrap:wrap;margin-top:12px;\"\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e📄 NEJM Phase 2 Full Text\u003c\/a\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\"\u003e📊 TRIUMPH-1 Data\u003c\/a\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 3: Research Dosing Protocol ────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M9 5H7a2 2 0 0 0-2 2v12a2 2 0 0 0 2 2h10a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2h-2\"\u003e\u003c\/path\u003e\u003crect x=\"9\" y=\"3\" width=\"6\" height=\"4\" rx=\"1\"\u003e\u003c\/rect\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eResearch Dosing Protocol\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003e⚠ Research use only — not medical advice\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cdiv class=\"reta-warn\" style=\"margin-bottom:20px;\"\u003e\n\u003cstrong\u003eResearch Reference Only.\u003c\/strong\u003e Protocol derived from Phase 2 and Phase 3 clinical trial data. Strictly for in-vitro or pre-clinical research.\u003c\/div\u003e\n        \u003cdiv class=\"recon-box\"\u003e\n          \u003ch3\u003eReconstitution — 10 mg Vial (SKU: RT10)\u003c\/h3\u003e\n          \u003cdiv class=\"recon-formula\"\u003e10 mg + 2 mL BAC Water = 5 mg\/mL\u003c\/div\u003e\n          \u003cdiv class=\"recon-detail\"\u003e1 unit (U-100) = 0.01 mL = 50 µg  ·  Store at 2–8 °C  ·  Use within 28 days\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eEscalation Schedule (Phase 2 Protocol)\u003c\/h3\u003e\n        \u003ctable class=\"dose-table\"\u003e\n          \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePhase\u003c\/th\u003e\n\u003cth\u003eWeekly Dose\u003c\/th\u003e\n\u003cth\u003eUnits (U-100)\u003c\/th\u003e\n\u003cth\u003eVolume\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n          \u003ctbody\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 1–2\u003c\/td\u003e\n\u003ctd\u003e0.5 mg\u003c\/td\u003e\n\u003ctd\u003e10 U\u003c\/td\u003e\n\u003ctd\u003e0.10 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 3–4\u003c\/td\u003e\n\u003ctd\u003e1 mg\u003c\/td\u003e\n\u003ctd\u003e20 U\u003c\/td\u003e\n\u003ctd\u003e0.20 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 5–8\u003c\/td\u003e\n\u003ctd\u003e2 mg\u003c\/td\u003e\n\u003ctd\u003e40 U\u003c\/td\u003e\n\u003ctd\u003e0.40 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 9–12\u003c\/td\u003e\n\u003ctd\u003e4 mg\u003c\/td\u003e\n\u003ctd\u003e80 U\u003c\/td\u003e\n\u003ctd\u003e0.80 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr class=\"max-row\"\u003e\n\u003ctd class=\"phase-col\"\u003eWeek 13+\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e160 U (2 syringes)\u003c\/td\u003e\n\u003ctd\u003e1.60 mL\u003c\/td\u003e\n\u003ctd\u003eMax — do not exceed\u003c\/td\u003e\n\u003c\/tr\u003e\n          \u003c\/tbody\u003e\n        \u003c\/table\u003e\n        \u003ca class=\"calc-cta\" href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\"\u003e\n          \u003cdiv class=\"calc-cta-text\"\u003e\n\u003cstrong\u003e🧮 MVLabs.mx Peptide Calculator\u003c\/strong\u003e\u003cspan\u003eEnter your vial size and BAC water to auto-calculate units \u0026amp; volume for any dose\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"calc-cta-btn\"\u003eOpen Calculator →\u003c\/div\u003e\n        \u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n  \u003c!-- ── Section 4: Safety ────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z\"\u003e\u003c\/path\u003e\u003cline x1=\"12\" y1=\"9\" x2=\"12\" y2=\"13\"\u003e\u003c\/line\u003e\u003cline x1=\"12\" y1=\"17\" x2=\"12.01\" y2=\"17\"\u003e\u003c\/line\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eSafety Profile \u0026amp; Tolerability\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003ePhase 2 adverse event data — research reference\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cp\u003eAdverse events in Phase 2 were predominantly gastrointestinal, dose-dependent, and mostly mild-to-moderate in severity — occurring primarily during dose escalation.\u003c\/p\u003e\n        \u003ch3\u003eMost Common Adverse Events (8 mg group, Phase 2)\u003c\/h3\u003e\n        \u003cdiv class=\"se-bar-wrap\"\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eNausea\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:42%\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~42%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eDiarrhea\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:22%;background:#5ab4cc\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~22%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eVomiting\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:19%;background:#5ab4cc\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~19%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eConstipation\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:15%;background:#96cee0\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~15%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eDecreased appetite\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:32%;background:#0e4f68\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~32%\u003c\/span\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eKey Safety Notes\u003c\/h3\u003e\n        \u003cul\u003e\n          \u003cli\u003eGI adverse events primarily occur during dose escalation — not at steady state\u003c\/li\u003e\n          \u003cli\u003eNo significant hypoglycemia in non-diabetic subjects\u003c\/li\u003e\n          \u003cli\u003eHeart rate increase: +2–4 bpm at higher doses\u003c\/li\u003e\n          \u003cli\u003eNo serious pancreatitis events in Phase 2\u003c\/li\u003e\n          \u003cli\u003eDiscontinuation rates: 6–16% depending on dose\u003c\/li\u003e\n        \u003c\/ul\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 5: Reconstitution ──────────────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M14.5 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7.5L14.5 2z\"\u003e\u003c\/path\u003e\u003cpolyline points=\"14 2 14 8 20 8\"\u003e\u003c\/polyline\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eReconstitution \u0026amp; Storage Guide\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003eStep-by-step lab preparation reference\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cdiv class=\"recon-box\"\u003e\n          \u003ch3\u003eStandard Reconstitution\u003c\/h3\u003e\n          \u003cdiv class=\"recon-formula\"\u003e10 mg vial + 2 mL Bacteriostatic Water\u003c\/div\u003e\n          \u003cdiv class=\"recon-detail\"\u003e= 5 mg\/mL (5,000 µg\/mL)  ·  1 U-100 unit = 50 µg  ·  1 mL = 5 mg\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eStep-by-Step Procedure\u003c\/h3\u003e\n        \u003col\u003e\n          \u003cli\u003eAllow the lyophilized vial to reach room temperature (~15 min)\u003c\/li\u003e\n          \u003cli\u003eClean rubber stoppers with 70% isopropyl alcohol\u003c\/li\u003e\n          \u003cli\u003eDraw 2.0 mL of bacteriostatic water into a clean 3 mL syringe\u003c\/li\u003e\n          \u003cli\u003eInject water \u003cstrong\u003eslowly down the side\u003c\/strong\u003e — do not spray onto powder\u003c\/li\u003e\n          \u003cli\u003eGently swirl (no vortex\/shake) until dissolved — clear and colorless\u003c\/li\u003e\n          \u003cli\u003eDiscard if cloudiness or particles visible\u003c\/li\u003e\n          \u003cli\u003eLabel with reconstitution date, store at \u003cstrong\u003e2–8 °C\u003c\/strong\u003e\n\u003c\/li\u003e\n        \u003c\/ol\u003e\n        \u003ch3\u003eStorage Conditions\u003c\/h3\u003e\n        \u003ctable class=\"dose-table\"\u003e\n          \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eState\u003c\/th\u003e\n\u003cth\u003eTemperature\u003c\/th\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n          \u003ctbody\u003e\n            \u003ctr\u003e\n\u003ctd\u003eLyophilized (powder)\u003c\/td\u003e\n\u003ctd\u003e−20 °C (freezer)\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003ctd\u003eKeep desiccated \u0026amp; dark\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd\u003eLyophilized (powder)\u003c\/td\u003e\n\u003ctd\u003e2–8 °C (fridge)\u003c\/td\u003e\n\u003ctd\u003e3–6 months\u003c\/td\u003e\n\u003ctd\u003eAvoid freeze-thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr class=\"max-row\"\u003e\n\u003ctd\u003e\u003cstrong\u003eReconstituted\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2–8 °C (fridge)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDo not freeze\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n          \u003c\/tbody\u003e\n        \u003c\/table\u003e\n        \u003ca class=\"calc-cta\" href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\"\u003e\n          \u003cdiv class=\"calc-cta-text\"\u003e\n\u003cstrong\u003e🧮 Calculate Your Dose\u003c\/strong\u003e\u003cspan\u003eUse the MVLabs.mx Peptide Calculator to convert mg doses to syringe units instantly\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"calc-cta-btn\"\u003eOpen Calculator →\u003c\/div\u003e\n        \u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 6: Literature ────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M4 19.5v-15A2.5 2.5 0 0 1 6.5 2H20v20H6.5a2.5 2.5 0 0 1 0-5H20\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eResearch Literature \u0026amp; Official Sources\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003ePeer-reviewed studies, Lilly data, clinical trials\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cul\u003e\n          \u003cli\u003e\n\u003cstrong\u003eJastreboff AM et al.\u003c\/strong\u003e \"Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.\" \u003cem\u003eN Engl J Med.\u003c\/em\u003e 2023;389:514-526. \u003ca class=\"ref-chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e🔗 NEJM\u003c\/a\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eEli Lilly.\u003c\/strong\u003e TRIUMPH-1 Phase 3 Topline Results, 2025. \u003ca class=\"ref-chip\" href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\"\u003e🔗 Lilly\u003c\/a\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eZhang Y et al.\u003c\/strong\u003e \"Structural insights into triple agonism at GLP-1R, GIPR and GCGR by retatrutide.\" \u003cem\u003eCell Discovery.\u003c\/em\u003e 2024. \u003ca class=\"ref-chip\" href=\"https:\/\/www.nature.com\/articles\/s41421-024-00700-0\" target=\"_blank\" rel=\"noopener\"\u003e🔗 Nature\u003c\/a\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003ePMC Review 2025.\u003c\/strong\u003e \"Retatrutide — A Game Changer in Obesity Pharmacotherapy.\" \u003ca class=\"ref-chip\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12190491\/\" target=\"_blank\" rel=\"noopener\"\u003e🔗 PMC\u003c\/a\u003e\n\u003c\/li\u003e\n        \u003c\/ul\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Final CTA ─────────────────────────────────────── --\u003e\n  \u003ca class=\"calc-cta\" href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\" style=\"text-decoration:none;display:flex;\"\u003e\n    \u003cdiv class=\"calc-cta-text\"\u003e\n\u003cstrong\u003e🧮 MVLabs.mx Peptide Calculator\u003c\/strong\u003e\u003cspan\u003eCalculate exact units and volumes for Retatrutide and 50+ research peptides\u003c\/span\u003e\n\u003c\/div\u003e\n    \u003cdiv class=\"calc-cta-btn\"\u003eOpen Calculator →\u003c\/div\u003e\n  \u003c\/a\u003e\n\n  \u003c!-- ── Product Specs ──────────────────────────────────── --\u003e\n  \u003cdiv style=\"background:#f8fafc;border:1.5px solid #cce8f2;border-radius:14px;padding:20px 24px;margin:24px 0;\"\u003e\n    \u003ch3 style=\"color:#0e4f68;font-size:14px;text-transform:uppercase;letter-spacing:0.07em;margin:0 0 12px;\"\u003eProduct Specifications\u003c\/h3\u003e\n    \u003ctable style=\"width:100%;border-collapse:collapse;font-size:13.5px;\"\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;width:40%;\"\u003ePurity\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003e≥99% HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eFormat\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eQuantity\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003e10 mg per vial\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eSKU\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003eRT10\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eStorage\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003e2–8°C · Protect from light\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eIntended use\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#b45309;\"\u003eResearch use only — not for human consumption\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003c\/table\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Footnotes ─────────────────────── --\u003e\n  \u003cdiv class=\"reta-footnotes\"\u003e\n    \u003ch4\u003eReferences\u003c\/h4\u003e\n    \u003col class=\"fn-list\"\u003e\n      \u003cli data-n=\"[1]\"\u003eJastreboff AM et al. N Engl J Med. 2023;389:514-526. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003eDOI\u003c\/a\u003e\n\u003c\/li\u003e\n      \u003cli data-n=\"[2]\"\u003eFinan B et al. Sci Transl Med. 2013. [Dual\/triple agonist rationale]\u003c\/li\u003e\n      \u003cli data-n=\"[3]\"\u003eZhang Y et al. Cell Discovery. 2024. \u003ca href=\"https:\/\/www.nature.com\/articles\/s41421-024-00700-0\" target=\"_blank\" rel=\"noopener\"\u003eNature\u003c\/a\u003e\n\u003c\/li\u003e\n    \u003c\/ol\u003e\n    \u003cp style=\"font-size:11px;color:#456d80;margin-top:16px;\"\u003e© 2026 MVLabs.mx. For research and educational purposes only. Not intended for human consumption. Always consult a licensed healthcare professional. \u003ca href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\"\u003ePeptide Calculator\u003c\/a\u003e\u003c\/p\u003e\n  \u003c\/div\u003e\n\n\u003c\/div\u003e\u003c!-- \/reta-page --\u003e","brand":"MV Labs","offers":[{"title":"10 mg","offer_id":44559030976627,"sku":"RT10","price":3200.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/3577\/6371\/files\/Retadetail2.png?v=1773020778"}],"url":"https:\/\/mvlabs.mx\/collections\/frontpage.oembed","provider":"MV Labs","version":"1.0","type":"link"}